Note d’information scientifique, 17 juin 2021
Paraguay muestra avances en el compromiso asumido, de avanzar hacia la Salud Uni¬versal. La experiencia ha demostrado que el proceso puede acelerarse cuando existe un fuerte involucramiento social. En este marco se realizó un llamado a los líderes del MSPYBS, la sociedad civil y público en gener...al para lograr un sólido compromiso con las acciones que nos permitan avan¬zar hacia la salud para todos y todas en ámbitos específicos. El propósito fue el de abrir un espacio de diálogo que genere propuestas concretas para sentar las bases de un sistema de Salud Universal. En este marco se realizó un llamado a los líderes del MSPYBS, la sociedad civil y público en general para lograr un sólido compromiso con las acciones que nos permitan avan¬zar hacia la salud para todos y todas en ámbitos específicos. El propósito fue el de abrir un espacio de diálogo que genere propuestas concretas para sentar las bases de un sistema de Salud Universal.
more
CORONAVIRUS COVID-19 Manejo Clínico en Pediatría
Paraguay
Mise en oeuvre de l’alerte précoce et réponse notamment la surveillance fondée sur les évènements
: Déclaration conjointe de l’OMS et de l’UNICEF encourageant une meilleure intégration des produits pharmaceutiques sensibles à la température dans la chaîne d’approvisionnement en produits de santé dans les cas appropriés, 19 novembre 2020
Le présent document est une mise à jour du document d’information scientifique publié le 29 mars 2020 intitulé Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations et comprend les nouvelles don...nées scientifiques disponibles sur la transmission du SARS-COV-2, le virus responsable de la COVID-19.
more
La publicación consiste en un instrumento de gestión, que permite unificar los criterios de manejo clínico operacional en la lucha contra la tuberculosis y contribuye a que esta enfermedad deja de ser un problema de salud pública en nuestro país.
The occurrence of a high percentage of couterfeit medicines on the global medicines market is often attributed to a lack of effective regulation and a weak enforcement capacity. This review, while focusing on counterfeit medicines and medical devices in developing countries, will present information... on their impact and how these issues can be addressed by regulation and control of the supply chain using technology appropriate to the developing world.
more
Original text from 2008, updated in 2012. This document marks the beginning of a structured approach to safety assessment of GE foods, which are yet to be approved in our country. It is understood that many changes will become necessary and will be incorporated as we progress. This document will ho...wever, remain an important milestone in the process towards safety evaluation of food derived from GE plants in India.
more
2nd edition .
This Framework applies to the sharing of H5N1 and other influenza viruses with human pandemic potential and the sharing of benefits. This Framework does not apply to seasonal influenza viruses or other non-influenza pathogens or biological substances that may be contained in clinical ...specimens shared under this Framework
This second edition of the Pandemic Influenza Preparedness (PIP) Framework reflects an amendment to Annex 2, Standard Material Transfer Agreement 2, Footnote 1, that was adopted by the Seventy-second World Health Assembly in May 2019.The amendment clarifies that, under certain circumstances, the indirect use of PIP Biological Materials will require the conclusion of an SMTA2. The amendment is in effect from the closure of the Seventy-second World Health Assembly (28 May 2019).
more
The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys...tems to anticipate and mitigate stresses across NCD medicine supply chains. The full range of upstream and downstream impacts are investigated, including: manufacturing; procurement, importation and last mile delivery; patient-level effects through affordability and availability; and the effects on NCD medicine availability by category of disease. The report culminates in recommended actions and interventions for key stakeholders in the NCD pharmaceutical supply chain, including governments, regulatory authorities, manufacturers and the private sector; as well as directions for future research for improving access and supply chain access resilience.
more